Study design and participants
stroke, vessel occlusion, acute ischemic stroke, cardio-embolism
STROKE
The RESCUE BT trial was a prospective, investigator-initiated, double-blind, randomized, placebo-controlled trial aimed at assessing the safety and efficacy of intravenous tirofiban versus placebo prior to EVT in acute ischemic stroke with large vessel occlusion from 55 hospitals in China between October 2018 and October 2021. The trial protocol and primary results had been published [Patients who were aged 18 years old or more, presenting with occlusion of the internal carotid artery (ICA) or middle cerebral artery (MCA) -M1/M2 within 24 h of time last known well, and with a stroke etiology of cardio-embolism were included in the present study. For patients who experienced a stroke within 48 h of Direct Oral Anticoagulant (DOAC) intake, they did not receive thrombolytic treatment. In patients with a history of warfarin anticoagulation therapy, intravenous thrombolysis was considered if INR ≤ 1.7 or a PT < 15 s, with the informed consent of patients or their family members.